Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

A interesting discussion of Brilacidin in this new antibiotic and drug resistance review paper. Published 1 September in Microbiology journal. I add bold.
The world continues to discover Brilacidin. I am happy to own some of it.

"Brilacidin (PMX30063) is a small arylamide foldamer that mimics naturally occurring AMPs (Fig. 10). It was optimized for its activity against S. aureus and is composed of a planar scaffold decorated with two trifluoromethane hydrophobic substitutions and four positive guanadinyl and pyridinyl substitutions [275]. It has been shown that brilacidin exposure causes a rapid depolarization of the membrane at a comparable rate to that of the clinically used lipopeptide DAP. Further transcriptomic analysis showed that, like DAP, brilacidin causes induction of the cell-wall-stress two-component systems
VraRS and WalRK, a phenomenon strongly associated with lipid II-targeting antibiotics [275–277]. A serial passage resistance study showed that no significant increase in MIC occurred over a period of 16?days, demonstrating that S. aureus struggles to evolve resistance to brilacidin. Two phase II clinical trials have evaluated the efficacy and safety of brilacidin compared with DAP in subjects with ABSSSIs (NCT02052388 and NCT01211470). The primary endpoint of early clinical response, defined as a >20?% reduction in lesion size, was high (>90?%) in patients treated with IV brilacidin and comparable to that of the DAP-treated group. No serious AEs were documented, and all treatment-emergent AEs were mild or transient in nature, indicating an appropriate safety profile [278]. In 2015, the developer, Innovation Pharmaceuticals, announced?a phase III trial further investigating brilacidin for treatment of ABSSSIs, but this has been delayed. Therapeutic use of brilacidin is being investigated in phase II trials for oral mucositis (NCT02324335), coronavirus disease 2019 (COVID-19) (NCT04784897), phase I investigation for colonic delivery (NCT04240223) and pre-clinical development for fungal infections."
https://www.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.001387